1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 84,00 | 84,50 | 12:49 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 12:18 | Barclays initiates coverage on Abivax stock with Overweight rating | 1 | Investing.com | ||
| ABIVAX SA ADR Aktie jetzt für 0€ handeln | |||||
| Fr | Guggenheim raises Abivax stock price target to $150 on obefazimod potential | 21 | Investing.com | ||
| Di | Leerink Partners raises Abivax stock price target to $115 on IBD drug potential | 11 | Investing.com | ||
| 06.10. | Why Is Abivax Stock Trading Higher On Monday? | 9 | Benzinga.com | ||
| 06.10. | Top 1% Biotech Abivax Surges On 'Compelling' Results In A Highly Watched Disease | 13 | Investor's Business Daily | ||
| 06.10. | Abivax stock jumps after positive ulcerative colitis trial results | 6 | Investing.com | ||
| 06.10. | Abivax-Aktie legt nach positiven Studiendaten zu Colitis ulcerosa kräftig zu | 12 | Investing.com Deutsch | ||
| 06.10. | Abivax: Citizens bestätigt hohes Kursziel nach positiven Sicherheitsdaten | 27 | Investing.com Deutsch | ||
| 06.10. | Citizens reiterates Abivax stock rating with $114 price target | 3 | Investing.com | ||
| 06.10. | EQS-News: ABIVAX: Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Induction Trial Results in Participants With and Without Prior Inadequate Response to Advanced Therapies | 399 | EQS Group (EN) | EQS-News: ABIVAX
/ Key word(s): Conference/Study results
Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Induction Trial Results in Participants With and Without... ► Artikel lesen | |
| 06.10. | Abivax Reports Positive 8-Week Results From Phase 3 Trials Of Obefazimod In Ulcerative Colitis | 21 | RTTNews | ||
| 05.10. | EQS-News: ABIVAX: Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Trial Results with Updated Safety Data | 565 | EQS Group (EN) | EQS-News: ABIVAX
/ Key word(s): Conference/Study results
Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Trial Results with Updated Safety Data
05.10.2025... ► Artikel lesen | |
| 01.10. | Citizens JMP Raises PT on ABIVAX Société Anonyme (ABVX) Stock | 17 | Insider Monkey | ||
| 29.09. | EQS-News: ABIVAX: Abivax Announces Acceptance of Additional Late-Breaking Abstract from the ABTECT Phase 3 Induction Trials to be Presented at 2025 United European Gastroenterology (UEG) Meeting | 379 | EQS Group (EN) | EQS-News: ABIVAX
/ Key word(s): Conference
Abivax Announces Acceptance of Additional Late-Breaking Abstract from the ABTECT Phase 3 Induction Trials to be Presented at 2025 United... ► Artikel lesen | |
| 25.09. | Abivax stock price target raised to $114 from $95 at JMP Securities | 10 | Investing.com | ||
| 25.09. | JMP Securities hebt Kursziel für Abivax auf 114 US-Dollar an | 8 | Investing.com Deutsch | ||
| 23.09. | Abivax präsentiert Phase-3-Daten für Obefazimod auf UEG-Kongress | 18 | Investing.com Deutsch | ||
| 23.09. | Abivax to present obefazimod phase 3 data at UEG meeting in October | 1 | Investing.com | ||
| 23.09. | EQS-News: ABIVAX: Abivax Announces Presentation of Late-Breaking Abstract for Obefazimod from the ABTECT Phase 3 Induction Trials at 2025 United European Gastroenterology (UEG) Meeting | 437 | EQS Group (EN) | EQS-News: ABIVAX
/ Key word(s): Conference
Abivax Announces Presentation of Late-Breaking Abstract for Obefazimod from the ABTECT Phase 3 Induction Trials at 2025 United European... ► Artikel lesen | |
| 23.09. | Abivax stock rating reiterated at Market Outperform by JMP | 6 | Investing.com |
1 2 3 4 5 Weiter >>
103 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ARCUTIS BIOTHERAPEUTICS | 20,050 | 0,00 % | Arcutis Biotherapeutics, Inc.: FDA Approves Arcutis' ZORYVE (roflumilast) Cream 0.05% for the Treatment of Atopic Dermatitis in Children Ages 2 to 5 | ZORYVE cream 0.05% provides rapid and effective relief of mild to moderate atopic dermatitis in children ages 2 to 5 and is safe and well toleratedOnce-daily, steroid-free cream can be used anywhere... ► Artikel lesen | |
| 89BIO | 14,800 | 0,00 % | Roche Launches Tender Offer To Acquire 89bio For $14.50/shr Plus CVR | SOUTH SAN FRANCISCO (dpa-AFX) - Roche (RHHBY, RO.SW, ROG.SW) announced that it has launched a tender offer to acquire all outstanding common shares of 89bio, Inc. (ETNB). The offer includes... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 5,305 | 0,00 % | RECURSION PHARMACEUTICALS INC zündet den Turbo jetzt! | ||
| BEAM THERAPEUTICS | 26,340 | 0,00 % | Jefferies stuft Beam Therapeutics auf "Buy": Kommende Katalysatoren im Fokus | ||
| MOONLAKE IMMUNOTHERAPEUTICS | 10,290 | 0,00 % | Oppenheimer senkt Kursziel für Moonlake Immunotherapeutics nach durchwachsenen Studienergebnissen | ||
| LENZ THERAPEUTICS | 38,740 | 0,00 % | Piper Sandler raises LENZ Therapeutics stock price target to $67 on VIZZ launch | ||
| MINERALYS THERAPEUTICS | 42,170 | +7,06 % | Mineralys Therapeutics: Aktie erreicht Rekordhoch von 41,11 USD | ||
| BIONTECH | 89,40 | +1,76 % | BioNTech Aktie zeigt Stärke: Es wird spannend! | Seit dem letzten 4investors.de-Chartcheck zur BioNTech Aktie hat sich einiges getan. Der Aktienkurs des Mainzer Biotech-Konzerns ist an der NASDAQ um rund 9 Dollar gestiegen, hat die 20- und 50-Tage-Linie... ► Artikel lesen | |
| ARCELLX | 86,80 | 0,00 % | Arcellx, Inc.: Arcellx Announces Its Participation at TD Cowen's 6th Annual Oncology Innovation Summit and Its Investor Event During EHA2025 | Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 52,45 | 0,00 % | Apogee Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $345 Million | SAN FRANCISCO and BOSTON, Oct. 10, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with potential for... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 49,740 | 0,00 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Second Quarter 2025 Financial Results and Recent Highlights | Aligned with FDA on del-brax accelerated and full approval pathways for FSHD, reported positive topline data from Phase 1/2 FORTITUDE trial, and initiated global... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 21,320 | -5,87 % | UBS bestätigt Kaufempfehlung für Summit Therapeutics vor ESMO-Daten | ||
| COGENT BIOSCIENCES | 16,250 | 0,00 % | Cogent Biosciences, Inc.: Cogent Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | WALTHAM, Mass. and BOULDER, Colo., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined... ► Artikel lesen | |
| BICARA THERAPEUTICS | 17,780 | 0,00 % | Bicara Therapeutics Inc.: Bicara Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update | Updated data from Phase 1/1b trial presented at 2025 ASCO Annual Meeting demonstrated deep and durable responses in 1L HPV-negative R/M HNSCC Data from additional Phase 1/1b expansion cohorts evaluating... ► Artikel lesen | |
| LEXEO THERAPEUTICS | 8,240 | 0,00 % | Lexeo Therapeutics Announces Progress in FDA Discussions for Accelerated Approval Pathway and Positive Interim Clinical Data for LX2006 in Friedreich Ataxia Cardiomyopathy | U.S. Food and Drug Administration (FDA) open to pooling data from ongoing Phase I/II studies of LX2006 with pivotal data to support a Biologics License Application (BLA) for Accelerated Approval Interim... ► Artikel lesen |
Das Unternehmen ABIVAX SA ADR kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell +2,47 % bei einem Aktienkurs von 83,00 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ABIVAX SA ADR finden Sie auf Wallstreet Online.